A new 6-month treatment for multidrug-resistant tuberculosis
Treatments studied
Part of Infections clinical trials.
This trial tests a new 6-month treatment for people with multidrug-resistant tuberculosis (MDR-TB). It aims to see if this shorter treatment works well and can be used in France, offering a quicker option for recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have tuberculosis that is resistant to rifampicin (confirmed by a lab test)
- You are willing to use effective birth control during treatment and for a few months after (if applicable)
- You have health insurance, state medical aid (AME), or are applying for emergency medical care
- You are not allergic or intolerant to any of the study drugs
- You do not have severe heart rhythm problems or severe nerve damage
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter treatment for drug-resistant tuberculosis (TB) using the medicine Pretomanid. It aims to find a more manageable cure for people whose TB does not respond to the standard first-line drug, rifampicin.
This trial tests a shorter course of three drugs (bedaquiline, moxifloxacin, and pyrazinamide) for people with newly diagnosed, drug-sensitive TB. It aims to see how quickly the drugs kill the bacteria in the first few days of treatment.
This trial tests a 6-month all-oral combination of four drugs (bedaquiline, delamanid, linezolid, and levofloxacin) for people with drug-resistant tuberculosis. It aims to see if this shorter, simpler regimen works well and is safe.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This trial tests a three-drug combination (bedaquiline, delamanid, and linezolid) to see if it's safe and works well for people with multi-drug resistant or rifampicin-resistant tuberculosis. It may offer a new treatment option if standard drugs aren't working.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
Hear when a new MDR-TB trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.